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Treatment of AIDS in conﬂict-affected settings: a failure
ofimagination
World AIDS Day last month focused on the impact of HIV
on  women  and  girls.  The  particular  vulnerability  of
women to HIV during and after conﬂict is well-recognised.
Yet  conﬂict-affected  communities  have  been  excluded
from international discourse around AIDS care and fund-
ing for treatment in resource-poor settings. Of more than
10 000  abstracts  published  for  the  2004  International
AIDS Conference
1 in Bangkok, only one reported on treat-
ment of AIDS in a conﬂict setting.
One in four African countries, many with a high preva-
lence  of  HIV,  are  currently  affected  by  conﬂict.
2 In  the
Democratic Republic of Congo alone, 24 million people
are directly affected by conﬂict and almost 4 million are
displaced. Even in apparently stable countries and com-
munities,  AIDS  treatment  programmes  can  experience
instability and conﬂict in the coming years—the risk exac-
erbated by poverty and HIV.
Conﬂict-affected populations are highly vulnerable to
HIV infection and there is increasing recognition of the
importance  of  addressing  this  situation.
3 Combatants
have extremely high rates of HIV and sexually transmitted
infections.
4 Rape  is  frequent  and  has  been  used  as  a
weapon of war.
5 Vulnerability is compounded by poverty,
homelessness, breakdown of social supports, and lack of
access to health care. In Sierra Leone and Angola, the iso-
lation of the populations during the conﬂict appears to
have paradoxically protected them from the accelerating
epidemic in neighbouring countries, but the postconﬂict
period poses a great risk to the populations, during which
intervention is essential.
What explains the inaction by the international commu-
nity to ensure AIDS care and treatment reaches the mil-
lions living in conﬂict-affected settings? There has been a
failure to invest in and develop models that show the fea-
sibility of treatment in difﬁcult settings. We risk repeating
the  tragic  failures  of  imagination  that  led  to  delay  in
acceptance of the role of treatment in stable resource-
poor settings in the 1990s.
Drawing on lessons learnt from treating tuberculosis in
conﬂict settings,
6 Médecins Sans Frontières is providing
comprehensive  care,  including  antiretroviral  treatment,
to AIDS  patients  in  Bukavu  in  eastern  Democratic
Republic of Congo. Particular attention is paid to involv-
ing the patient in decisions around care and treatment.
Heavy ﬁghting erupted in May, 2004, leading to tempo-
rary evacuation of health staff and signiﬁcant displace-
ment of the population . Dedicated local staff maintained
a minimum programme and an announcement was made
on local radio to inform patients that the clinic would be
open  for  the  distribution  of  antiretroviral  treatment.
Delivery  ofantiretroviral  therapy  with  good  adherence
was  maintained  throughout.  No  patients  were  lost  to
follow-up and treatment has continued without disrup-
tion  since  the  situation  stabilised.  Lessons  learned  will
further improve the programme’s resilience to future dis-
ruption.
Conﬂict-affected settings include a vast range of con-
texts and there is a risk that all are considered equally dif-
ﬁcult to work in. Paradoxically, the provision of treatment
itself  might  be  simpler  in  certain  conﬂict-affected  set-
tings. Refugees and internally displaced people in a closed
camp are easier to access than they would be in their rural
communities, allowing greater opportunity for provision
of care and of HIV-awareness activities. Further, there is a
lack of recognition that the now well-accepted rationale
for a comprehensive approach to HIV in stable settings,
with provision of treatment and prevention, has equal if
not greater validity in unstable settings.
Apart from the great needs of vulnerable civilian popula-
tions, particularly of women, a few points are speciﬁc to con-
ﬂict settings. It has been suggested that, for HIV-positive
combatants aware of their status but unable to access care,
the absence of hope of treatment means there is little to pre-
vent  them  from  acts  of  violence  and  sexual  abuse.
7
Paradoxically, calls for compulsory HIV tests in armed forces
8
might  then  increase  the  risk  of  violence  by  these  men.
Conversely  the  potential  for  treatment  could  become  a
reason for infected combatants and the population to seek
peace, or at least to protect a space for health-care provision.
Days of tranquillity have previously been granted by warring
parties
9 to  allow  poliovirus  vaccination  to  go  ahead,  and
community leaders in south Sudan have cited the need to
protect tuberculosis programmes in negotiating peace at
the local level.
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The availability of treatment offers a medium for raising
interest and engagement with combatants and the com-
munity around HIV testing and prevention messages. In
unstable settings failure to engage rapidly with popula-
tions might mean opportunities are lost. In conﬂict there
are many health priorities which, in the face of limited
resources, often compete. Concerns about risk of resist-
ance, lack of infrastructure, sustainability, and absence of
health staff are serious and valid, but not insurmountable.
The threats of development of resistance due to poorly
managed  public-treatment  programmes  are  much  dis-
cussed
10 and underlie concerns about provision of tubercu-
losis  and  AIDS  treatment  in  unstable  settings.  However,
unregulated drug markets are potentially even more harm-
ful.Recent experience in northern Afghanistan showed that
almost  70%  of  patients  entering  a  new  programme  for
tuberculosis  treatment  required  second-line  treatment,
having  previously  taken  inappropriate  tuberculosis  regi-
mens.  Antiretroviral  drugs  are  increasingly  available  in
resource-poor countries, and will be marketed wherever
there is demand. Nevirapine, which, when taken alone,
rapidly  engenders  resistance,
11 is  widely  available  and
likely  to  be  affordable  even  to  the  poorest.  Taken  as
monotherapy, this drug would seriously prejudice the suc-
cess of standard treatment regimens with major harm to
public health. Even where operationally difﬁcult, there-
fore, a managed programme would reduce harm through
provision of an alternative source of effective treatment.
The  use  of  simple  ﬁxed-dose  combinations  (for  both
tuberculosis and HIV) will simplify treatment while min-
imising risks of single drugs becoming available on the
market.
Robust drug-management systems that anticipate dis-
ruption will further reduce these risks. As long as patients
stop all antiretroviral drugs at the same time, resistance is
unlikely to develop and they will be able to restart the
same  treatment  when  the  situation  stabilises.  Careful
attention to education about the importance of correct
treatment,  through  counselling  and  use  of  radio  and
other media, along with free provision of treatment, will
help to ensure proper care while minimising the risks that
patients  will  buy  useless  treatments  should  the  pro-
gramme be disrupted. Involvement of people living with
HIV/AIDS  as  peer-educators  and  adherence  counsellors
reduces the need for trained health staff and helps ensure
a patient-centred approach to care.
Increased international resources are needed to address
prevention and treatment needs in conﬂict-affected popu-
lations. AIDS and tuberculosis treatments can be delivered
in difﬁcult settings, providing opportunities to promote
behavioural change, stigma reduction, hope, and peace.
Treatment programmes in stable settings must anticipate
and be able to withstand periods of disruption. Although
the  difﬁculties  and  risks  in  ensuring  treatment  options
must not be underestimated, they can be mitigated, and, if
the goal of having 3 million on treatment by 2005 is to be
met, they must be faced.
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Lyme disease, caused by the spirochaete Borrelia burgdor-
feri, is the most common vector-borne disease in the USA.
In 2002, 23763 cases were reported, with patients diag-
nosed  in  every  state  except  Montana,  Hawaii,  and
Oklahoma.
1 Most cases were concentrated in the north-
eastern, middle Atlantic, north central, and Paciﬁc states, a
pattern  remarkably  similar  to  the  distribution  of  Blue
States (Kerry) in the Presidential election in 2004 (ﬁgure).
Interestingly, the 19 states won by Kerry accounted for
over 95% of the total number of cases of Lyme disease.
The inauguration on Jan 20 of the victor, from Texas, the
Lone Star State, turned our minds to the cause of Lyme
disease.
Besides a different voting behaviour, most of the Red
States (Bush) also have a different kind of “Lyme disease”.
B burgdorferidoes not appear to be the cause of indigenous
cases of Lyme disease in any southernstate, besides, possi-
bly, Virginia. Although patients with suspected Lyme dis-
ease  in  the  south  often  have  a  skin  lesion  regarded  as
indistinguishable from erythema migrans, such rashes are
frequently preceded by the bite of an Amblyomma ameri-
canum tick (the Lone Star tick),
2 which is not a competent
vector for B burgdorferi.
3 Therefore, although fulﬁlling the
surveillance  case-deﬁnition  and  tabulated  as  Lyme  dis-
ease,
1 this  rash  is  more  appropriately  named  southern-
tick-associated rash illness (STARI). An alternative name is
Master’s  disease,  in  recognition  of  a  key  investigator,
Edwin Masters. The cause of STARI, although sometimes
attributed to a Borrelia species other than B burgdorferi,
remains unclear, as does its management.
4
It is important to recognise that the range of A ameri-
canumextends well beyond the Red States and as far north
along the eastern seaboard as Maine. “Lyme disease” cases
have followed the bite of this tick in both New Jersey and
Maryland,
5 suggesting that cases of erythema migrans in
some Blue States are not exclusively due to B burgdorferi
infection. A strong recommendation can be made for fur-
ther study of STARI and of Presidential elections.
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Lyme disease incidence in USA and Presidential election results, 2004
Upper=incidence (per 100 000) of Lyme disease by county of residence, USA,
2002;
1lower=US Presidential election results by state, 2004 (red=Bush,
blue=Kerry).
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